| Literature DB >> 32523052 |
Ido Refaeli1,2, Michael R Hughes3,4, Alvin Ka-Wai Wong1, Mei Lin Z Bissonnette5, Calvin D Roskelley6, A Wayne Vogl6, Sean J Barbour7, Benjamin S Freedman8,9,10, Kelly M McNagny11,12,13.
Abstract
Dominant and recessive mutations inEntities:
Mesh:
Substances:
Year: 2020 PMID: 32523052 PMCID: PMC7286918 DOI: 10.1038/s41598-020-64907-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Loss of Podxl from podocytes leads to severe proteinuria and kidney failure at ~6–7 weeks after birth. (A) Anti-mouse Podxl immunostaining of glomerular sections from Podxl△Pod and control mice. (B) Kaplan-Meier survival and Mendelian inheritance distribution from 8 litters with breeding scheme: Podxlf/fPod-Cre+/− X Podxlf/+Pod-Cre−/−. Expected distributions: Podxlf/fPod-Cre−/− OR Podxlf/+Pod-Cre−/− (25% + 25% = 50%) ~ wild-type; Podxlf/+Pod-Cre+/− (25%; PodxlHet-Pod); Podxlf/fPod-Cre+/− (25%; Podxl△Pod). Actual distributions: Podxlf/f (n = 25; 54%), PodxlHet-Pod (n = 11; 24%) and Podxl△Pod (n = 10; 22%) groups. (C) Images of whole, unperfused kidneys from control and Podxl∆Pod mice. (D) Urine albumin-creatinine ratio from 3-week-old wild-type (n = 4), PodxlHet-Pod (n = 3) and Podxl∆Pod (n = 3) littermates. ****p < 0.0001. (E) Urinary total protein-creatinine ratio from 3-week-old wild-type (n = 4), PodxlHet-Pod (n = 3) and Podxl∆Pod (n = 3) littermates. ****p < 0.0001. (F) Serum albumin concentration from 3-week-old controls (pooled wild-type and PodxlHet-Pod) (n = 3) and Podxl∆Pod (n = 3) littermates. *p < 0.05. (G) Undiluted urine SDS-PAGE from wild-type (n = 2) and Podxl△Pod (n = 2) mice. Bands at ~65–75 kDa correspond to albumin.
Figure 2Podxl△Pod mice present with progressive focal segmental glomerulosclerosis. (A) Masson’s trichrome stained kidney sections from Podxl△Pod (n = 10) and control (n = 5) mice. (B) Periodic acid-Schiff stained kidney sections from Podxl△Pod (n = 10) and control (n = 6) mice. (C) Transmission electron micrographs of podocyte foot processes in Podxl△Pod and control mice at days 1.5 and 10.5 post-partum. (D) Quantification of foot process frequency (defined as continuous membrane events separated by a slit diaphragm per unit length of basement membrane) in podocytes from Podxl△Pod and control mice. Number of TEMs quantified: control, P1.5 (n = 11), Podxl△Pod P1.5 (n = 31), control, P10.5 (n = 17), Podxl△Pod P10.5 (n = 17), Horizontal bars represent the mean. ****p < 0.0001.
Figure 3Podocin is mislocalized to the apical membrane domain in the absence of Podxl. Representative confocal micrographs from two experiments. Kidney sections (5 µm) from Podxl△Pod and control mice co-stained for podocalyxin and podocin and imaged using a Zeiss Airyscan confocal microscope. In the control micrographs, arrows denote apical-basal polarity in control podocytes. In the Podxl△Pod micrographs, lack of arrows indicates a loss of cellular polarity.
Figure 4Podxl is expressed before podocin (and Cre in Podxl△Pod mice) during nephrogenesis. (A) Representative confocal micrographs of Podxl (red) and podocin (green) expression in wild-type embryonic day 18.5 kidneys (n = 2 mice) from two separate experiments. Glomeruli are shown at the different stages of nephrogenesis. (B) Representative confocal micrographs showing native tomato fluorescence in post-natal day 1.5 kidneys from Pod-Cre+/−tdTomato+/− mice (Cre-reporter strain). CSB, comma-shaped body; SSB, S-shaped body; CLS, capillary loop stage; Mature, fully matured glomerulus.
Figure 5Podxl+/− mice have normal kidney architecture and function. (A) H&E staining (upper panels) and transmission electron micrographs (lower panels) of cortical kidney sections from age- and sex-matched wild-type (n = 2) and Podxl+/− (n = 2) mice. (B) Quantification of podocyte foot processes using transmission electron micrographs from age- and sex- matched wild-type (n = 2) and Podxl+/- (n = 2) mice. ****p < 0.0001 (C) Serum creatinine quantification from age- and sex-matched wild-type (n = 2) and Podxl+/- heterozygous (n = 2) mice. (D) Serum BUN quantification from age and sex matched wild-type (n = 2) and Podxl+/- (n = 2) mice. (E) Serum albumin quantification from age- and sex-matched wild-type (n = 2) and Podxl+/- (n = 2) mice. (F) Urine albumin:creatinine ratio from age- and sex-matched wild-type (n = 2) and Podxl+/- (n = 2) mice. (G) Quantification of Podxl transcripts using whole-kidney RNA from wild-type (n = 4) and Podxl+/- (n = 5) mice. Values are expressed as fold-change relative to the wild-type message. *p < 0.05 For all figure panels, 8-week old male and female littermates were examined.
Figure 6Podxl+/− mice are haploinsufficient with respect to puromycin aminonucleoside nephrosis. (A) Schematic of experimental nephropathy in Podxl+/− mice. Adult mice were treated with 2 intraperitoneal injections of puromycin aminonucleoside (450 mg/kg) on days 0 and 7. Sample collection occurred on day 14 (experimental endpoint). (B) Kaplan-Meyer survival analysis of wild-type and Podxl+/− mice treated with 2 doses (Day 0, 7) of 450 mg/kg puromycin aminonucleoside (PA). Logrank test *p < 0.05. (C) Masson’s trichrome stains of cortical kidney sections from wild-type and Podxl+/− mice treated with puromycin aminonucleoside. Yellow arrows on the upper and lower panels denotes segmental sclerosis and collapsing features, respectively. (D) Urine albumin:creatinine ratio from wild-type (n = 6) and Podxl+/− (n = 5) mice treated with puromycin aminonucleoside and vehicle controls (n = 5). **p < 0.01 (E) Serum creatinine levels from wild-type (n = 6) and Podxl+/− (n = 5) mice treated with puromycin aminonucleoside and vehicle controls (n = 3). **p < 0.01. (F) Serum albumin concentration from wild-type (n = 6) and Podxl+/− (n = 5) mice treated with puromycin aminonucleoside and vehicle controls (n =3). ***p < 0.001; ****p < 0.0001.
Figure 7Mice treated with puromycin aminonucleoside undergo podocyte loss. (A) p57 immunofluorescence staining of 5 µm cortical kidney sections from wild-type (n = 2) and Podxl+/− mice treated with puromycin aminonucleoside (n = 2). (B) Quantification of p57+ events per glomerular section. Multiple comparisons were performed between each wild-type and heterozygous sample, ****p < 0.0001.
Columbia classification of wild-type and Podxl+/− mice challenged with puromycin aminonucleoside and their corresponding urine albumin:creatinine ratios.
| n | Genotype | Tx Group | Variant | Pathology Phenotype | uACR (µg/mg) |
|---|---|---|---|---|---|
| 1 | +/+ | vehicle | normal | Unremarkable. | 1.53 |
| 2 | +/+ | vehicle | normal | Unremarkable. | 2.02 |
| 3 | +/+ | vehicle | normal | Unremarkable. | 1.93 |
| 4 | +/+ | PAN | normal | Unremarkable. | 1.56 |
| 5 | +/+ | PAN | collapsing | Minimal ATI, FSGS, NOS and some with collapsing features. | 2120 |
| 6 | +/+ | PAN | collapsing | FSGS, NOS and some with collapsing features but few FSGS lesions. Some tubular resorption droplets, small focus of interstitial inflammation. | 790 |
| 7 | +/+ | PAN | NOS | FSGS, NOS with podocyte hypertrophy but no shrunken tufts. Acute tubular injury. | n/a |
| 8 | +/+ | PAN | unremarkable | Rare podocyte resorption droplets. Otherwise unremarkable. | 59.5 |
| 9 | +/+ | PAN | NOS | Rare FSGS in gloms with tuft shrinkage and protein in Bowman’s space. Frequent tubular and podocyte resorption droplets, Mild ATI. | n/a |
| 10 | +/+ | PAN | unremarkable | FSGS, NOS lesion. Rare podocyte resorption droplets. Otherwise unremarkable. | n/a |
| 11 | +/+ | PAN | unremarkable | Rare pocodyte resorption droplets. Otherwise unremarkable. | 26.5 |
| 12 | +/− | PAN | collapsing | FSGS, NOS with segmental sclerosis made up of hylaine and matrix material. Some with collapsing features. Some with podocyte/visceral epithelial cell hyperplasia with vacuoliation and podoctye resorption droplets. Some with shrinking of glomerular tufts and filling of Bowman’s space with proteinaceous material. Diffuse actue tubular injury | n/a |
| 13 | +/− | PAN | collapsing | Severe ATI. Shrunken tufts with proteinaceous material in Bowman’s space. FSGS, NOS with podocyte hypertrophy and vacuolization some with collapsing like lesions. Some tubular and podocyte resorption droplets. | 3214 |
| 14 | +/− | PAN | NOS | FSGS, NOS lesion. Rare podocyte resorption droplets. Otherwise unremarkable. | 3422 |
| 15 | +/− | PAN | collapsing | Severe ATI. Shrunken tufts with proteinaceous material in Bowman’s space. FSGS, NOS with podocyte hypertrophy and vacuolization some and collapsing like lesions. Some tubular and podocyte resorption droplets. | n/a |
| 16 | +/− | PAN | collapsing | Severe ATI. Shrunken tufts with proteinaceous material in Bowman’s space. FSGS, NOS with podocyte hypertrophy and vacuolization some and collapsing like lesions. Some tubular and podocyte resorption droplets. | 5231 |
| 17 | +/− | PAN | collapsing | Mild ATI. Some FSGS, NOS and collapsing, some glomeruli with shrinkage. Tubular and podocyte resorption droplets. | 597.4 |
| 18 | +/− | PAN | collapsing | Severe ATI. Shrunken tufts with proteinaceous material in Bowman’s space. FSGS, NOS with podocyte hypertrophy and vacuolization some and collapsing like lesions. Some tubular and podocyte resorption droplets. | 4678 |
ATI, acute tubular injury; FSGS, focal segmental glomerulosclerosis; NOS, not otherwise specified; IF, interstitial fibrosis; TA, tubular atrophy.
For all cases: No IF/TA. All vessels normal. No/minimal global glomerular sclerosis. ATI associated with numerous proteinaceous casts with similarities to microcystic changes in severe cases.
n/a, urine not collected either due to severe disease (in case of Podxl+/- mice) or exceeding humane urine collection time window (in case of wild-type mice).
Figure 8The timing of Podxl deletion in podocytes affects the observed glomerular filtration phenotype. In wild-type mice, expression of Podxl at the SSB resolves the lateral junctions adjoining neighboring podocytes, enabling the expression and correct localization of slit diaphragm proteins. In Podxl−/− mice, failure to express Podxl renders podocytes incapable of resolving their junctional complexes. As a result, slit diaphragm proteins are expressed but fail to localize selectively to the basal domain, leading to an absence of filtration slit surface area. These mice therefore lack the ability to produce any urine. In Podxl△Pod mice, Podxl is expressed at the SSB, and thus podocytes are able to resolve their junctional complexes, allowing for the initial formation of slit diaphragms at the basal membrane domain. When Podxl is deleted by Cre at the CLS, slit diaphragm proteins mislocalize apically. Due to the high hydrostatic pressure generated by the perfusion of glomerular capillaries and the absence of adherens junctions on podocytes, slit diaphragms do not wall off. Instead, podocyte effacement occurs, leading to proteinuria. In Podxl+/− mice, the reduction in Podxl transcripts does not affect podocyte differentiation and they are able to complete morphogenesis similar to wild type podocytes, resulting in normal glomerular filtration at steady state. Following a second environmental hit, mutant podocytes are haploinsufficient and undergo effacement. As a result, they develop FSGS and proteinuria.